

# Orgovyx (relugolix)

Override(s)	Approval Duration
Prior Authorization	Initial requests: 6 months
Quantity Limit	Continuation requests: 6 months

Medications	Quantity Limit
Orgovyx (relugolix) tablets 120mg	1 tablet per day*

\*Initiation of therapy: May approve 3 additional tablets in the first month (28 days) of treatment for loading dose.

## APPROVAL CRITERIA

Initial requests for Orgovyx (relugolix) may be approved if the following criteria are met (Label, NCCN 1, 2A):

- I. Individual has a diagnosis of androgen-sensitive metastatic or advanced localized prostate cancer; **AND**
- II. One of the following clinical disease state presentations:
  - A. Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery; **OR**
  - B. Newly diagnosed androgen-sensitive metastatic disease; **OR**
  - C. Advanced localized disease unlikely to be cured by local primary intervention with either surgery or radiation with curative intent;

### **AND**

- III. Individual is using as androgen deprivation therapy; **AND**
- IV. Individual is using as a single agent or in combination (excluding those combinations which include fine-particle abiraterone or a combination regimen of EBRT and docetaxel); **AND**
- V. Individual has an ECOG status of 0 or 1.

Continuation requests for Orgovyx may be approved if the following criteria are met:

- I. Individual does not show evidence of progressive disease while on therapy; **AND**
- II. Individual has serum testosterone level less than 50 ng/dL.

## Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2024. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.

5. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 25, 2024.
  - a. Prostate Cancer. V3.2024. Revised March 8, 2024.
6. Orgovyx (relugolix) [prescribing information]. Brisbane, CA: Myovant Sciences Inc; December 2020.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.